Blue Ridge Research Center, L.L.C.

 
Blue Ridge Research Center, LLC, founded in 1995, is a private research entity in partnership with Roanoke Neurological Associates. Dr. John Gordon Burch is the President of Blue Ridge Research Center. All of our Neurologists participate in the conduction of Clinical Trials. BRRC has been conducting Phase II and Phase III clinical trials for over 12 years and clinical research activities are ongoing in many subspecialty areas including Epilepsy, Multiple Sclerosis, ADHD, Migraines, and Parkinson’s disease.
 

Our research coordinator Leslie Sainz, RN manages all details necessary for participation in our research studies. She reviews the details of the study on an individual basis with patients and/or family members. The intent of the study is explained, the inclusion and exclusion criteria for participation, the potential hazards and side effects of the medication being studied, and the financial or time commitment  requirements of the study. She will then review the details of the informed consent with patients and family members. She is assisted in her research efforts by Erin and Shari.

 

We are currently enrolling patients in the following studies. If you  have interest in one of them, please contact our study coordinator Leslie Sainz, RN at (540) 342-2929 or lsainz@roanokeneuro.com

 

Multiple Sclerosis

BioMS Maestro-03

 

  A double-blind, placebo-controlled multi-center study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.

 

To be eligible to participate, the following criteria must be met:

  • 18-65 years old
  • Diagnosis of SPMS
  • Absence of relapse in 3 months prior to baseline
  • Must be able to walk with or without aid

Parkinson’s Disease

 

A randomized, double-blind, placebo-controlled, 5-arm, parallel-group trial to assess rotigotine transdermal system dose response in subjects with advanced Parkinson’s disease.

 

To be able to participate in this study, the following criteria must be met:

 

  • Patients must have advanced Parkinson’s disease for at least 3 years.
  • Must be on carbidopa/levodopa (Sinemet)
  • Patients must experience the fluctuation of “On” and “Off” symptoms of Parkinson’s disease

MULTIPLE SCLEROSIS
Teva BRAVO

A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon B-1a (Avonex) in a rater-blinded design.

To be eligible to participate, the following criteria must be met:

  • 18-55 years old
  • Diagnosis of RRMS
  • Documented relapse in past 12 months, or two documented relapses in 24 months
  • Naïve to MS therapies with the exception of Copaxone, IVIG and Steroid treatment

For more information contact Leslie Sainz RN at 540-342-2929